Haake M, Schaefer T, Haack B, Vashist N, Genssler S, Harter P, Martens A, Wistuba-Hamprecht K, Wedekink F, Fischer B, Mittelbronn M, Levesque M, Cheng P, Dummer R, Weide B, Klar K, Leo E, Nimmerjahn F, Schuberth-Wagner C, Wischhusen J (2021)
Publication Type: Conference contribution
Publication year: 2021
Publisher: BMJ PUBLISHING GROUP
City/Town: LONDON
Pages Range: A597-A597
Conference Proceedings Title: JOURNAL FOR IMMUNOTHERAPY OF CANCER
DOI: 10.1136/jitc-2021-SITC2021.568
Immune checkpoint blockade (ICB) can achieve durable responses in a subgroup of patients with metastatic cancer, only. Poor immune effector cell infiltration into the tumor microenvironment is a major obstacle to successful therapy. Growth and differentiation factor 15 (GDF-15) is a divergent member of the TGF-β superfamily and has been linked to feto-maternal tolerance, anorexia but recently also to potent local immunosuppression under physiologic and pathophysiologic conditions. GDF-15 is overexpressed in a wide variety of tumors and may be key factor produced by tumors to prevent effective immune cell infiltration into the tumor and to potently block checkpoint inhibitor activity.
APA:
Haake, M., Schaefer, T., Haack, B., Vashist, N., Genssler, S., Harter, P.,... Wischhusen, J. (2021). TUMOR-DERIVED GDF-15 PREVENTS THERAPY SUCCESS OF CHECKPOINT INHIBITORS BY BLOCKING T-LYMPHOCYTE RECRUITMENT. In JOURNAL FOR IMMUNOTHERAPY OF CANCER (pp. A597-A597). LONDON: BMJ PUBLISHING GROUP.
MLA:
Haake, Markus, et al. "TUMOR-DERIVED GDF-15 PREVENTS THERAPY SUCCESS OF CHECKPOINT INHIBITORS BY BLOCKING T-LYMPHOCYTE RECRUITMENT." Proceedings of the JOURNAL FOR IMMUNOTHERAPY OF CANCER LONDON: BMJ PUBLISHING GROUP, 2021. A597-A597.
BibTeX: Download